【24h】

Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation

机译:雷诺嗪增强胺碘酮治疗近期发作的心房纤颤的功效

获取原文
获取原文并翻译 | 示例
           

摘要

Aims Amiodarone is used commonly for pharmacological cardioversion of atrial fibrillation (AF), but it is limited by moderate efficacy and delayed action. Ranolazine and amiodarone are markedly synergistic in suppressing experimental AF in vitro, yet the clinical efficacy of ranolazine combined with amiodarone for AF conversion has only undergone minimal investigation. This prospective, single-blinded, randomized study compared the safety and efficacy of ranolazine added to amiodarone vs. amiodarone alone for conversion of recent-onset AF. Methods and results We enroled 121 patients (64 ± 10 years, 45% male) with recent-onset (<48 h duration) AF who were eligible for pharmacological cardioversion. Patients received either 24 h amiodarone infusion (loading dose 5 mg/kg followed by maintenance dose of 50 mg/h; n = 60), or amiodarone infusion at the same dosage plus a single oral dose of ranolazine 1500 mg (n = 61). Patients in the amiodarone plus ranolazine group compared with the amiodarone-only group showed significantly higher conversion rates at 24 h (87 vs. 70%, respectively; P = 0.024) and at 12 h (52 vs. 32%; P = 0.021), and shorter time to conversion (10.2 ± 3.3 vs. 13.3 ± 4.1 h; P = 0.001). Subgroup analysis identified higher 24 h conversion in patients with left atrial (LA) diameter >46 mm who received the combination treatment vs. amiodarone alone (81 vs. 54%; P = 0.02), whereas the efficacy of the two interventions did not differ among patients with LA diameter ≤46 mm (P = 0.77). There was modest QT prolongation in both the groups, no serious adverse reactions, and no pro-arrhythmic events. Conclusion Addition of ranolazine to amiodarone was safe and well tolerated in this study, and it demonstrated efficacy superior to amiodarone alone for conversion of recent-onset AF. These findings may have clinical implications by offering a simple therapeutic manoeuvre to enhance amiodarone's effectiveness for conversion of AF.
机译:目的胺碘酮通常用于房颤(AF)的药理心脏复律,但受到中等疗效和延迟作用的限制。雷诺嗪和胺碘酮在体外抑制实验性AF方面具有明显的协同作用,但雷诺嗪联合胺碘酮对AF转化的临床疗效仅进行了最少的研究。这项前瞻性,单盲,随机研究比较了雷诺嗪与胺碘酮相比单独应用胺碘酮对近期发作的房颤的安全性和有效性。方法和结果我们招募了121例近期发作(<48 h持续时间)房颤的符合药理性电复律的患者(64±10岁,男性45%)。患者接受24小时胺碘酮输注(负荷剂量5 mg / kg,然后维持剂量50 mg / h; n = 60),或以相同剂量胺碘酮输注加雷诺嗪单次口服剂量1500 mg(n = 61) 。与仅使用胺碘酮的组相比,胺碘酮加雷诺嗪组的患者在24小时(分别为87 vs. 70%; P = 0.024)和12 h(52 vs. 32%; P = 0.021)时显示出更高的转化率。 ,转换时间更短(10.2±3.3 vs. 13.3±4.1 h; P = 0.001)。亚组分析发现,与单独使用胺碘酮相比,接受联合治疗的左房(LA)直径> 46 mm的患者,其24小时转化率更高(81 vs. 54%; P = 0.02),而两种干预的疗效无差异在LA直径≤46mm的患者中(P = 0.77)。两组患者的QT延长均中等,无严重不良反应,无心律失常事件。结论在本研究中向雷诺胺中添加雷诺嗪是安全的,并且耐受性良好,并且它证明了对于新近发作的房颤的转换优于单独使用胺碘酮的疗效。这些发现可能通过提供一种简单的治疗手段来增强胺碘酮对房颤转化的有效性,可能具有临床意义。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号